Combined pre-S deletion and core promoter mutations related to hepatocellular carcinoma: A nested case-control study in China

Hepatology Research

Volumn 41, Issue 1, 2011, Pages 54-63

  Qu, Li Shuai ^a   Liu, Tao Tao ^a   Jin, Fei ^a   Guo, Yan Mei ^a   Chen, Tao Yang ^b   Ni, Zheng Pin ^b   Shen, Xi Zhong ^a  

^a FUDAN UNIVERSITY   (China)

^b QIDONG LIVER CANCER INSTITUTE   (China)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; Mutation; Serum hepatitis B virus DNA levels

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CHINA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA SEQUENCE; ECHOGRAPHY; FOLLOW UP; GENE DELETION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER ANGIOGRAPHY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; RISK FACTOR; SEROLOGY; VIRUS MUTATION;

EID: 78650737532     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00732.x     Document Type: Article

References (34)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
3. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22-707 men in Taiwan. Lancet 1981; 2: 1129-33.
4. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
5. Chan HL, Tse CH, Mo F et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26: 177-82.
6. Yuen MF, Tanaka Y, Fong DY et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-8.
7. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83: 2059-73.
8. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 2010; 40: 14-30.
9. Chan HL, Hui AY, Wong ML et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-8.
10. Yang HI, Yeh SH, Chen PJ et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-43.
11. Chou YC, Yu MW, Wu CF et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008; 57: 91-7.
12. Yuen MF, Tanaka Y, Shinkai N et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 2008; 57: 98-102.
13. Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int 2007; 27: 1356-63.
14. Gao ZY, Li T, Wang J et al. Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma. J Gastroenterol 2007; 42: 761-8.
15. Chen CH, Hung CH, Lee CM et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007; 133: 1466-74.
16. Ito K, Tanaka Y, Orito E et al. T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin Infect Dis 2006; 42: 1-7.
17. Tanaka Y, Mukaide M, Orito E et al. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 2006; 45: 646-53.
18. Ming L, Thorgeirsson SS, Gail MH et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002; 36: 1214-20.
19. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996; 98: 2268-76.
20. Guo X, Jin Y, Qian G, Tu H. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol 2008; 49: 718-25.
21. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31: 1037-44.
22. Takahashi K, Aoyama K, Ohno N et al. The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 1995; 76 (Pt 12): 3159-64.
23. Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Brechot C. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999; 18: 4848-59.
24. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
25. Ferrari C, Cavalli A, Penna A et al. Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology 1992; 103: 255-63.
26. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130: 1153-68.
27. Fan YF, Lu CC, Chen WC et al. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 2001; 33: 277-86.
28. Georgi-Geisberger P, Berns H, Loncarevic IF et al. Mutations on free and integrated hepatitis B virus DNA in a hepatocellular carcinoma: footprints of homologous recombination. Oncology 1992; 49: 386-95.
29. Chen CH, Changchien CS, Lee CM et al. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. J Infect Dis 2008; 198: 1634-42.
30. Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004; 19: 670-5.
31. Tan CK, Law NM, Ng HS, Machin D. Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation. J Clin Oncol 2003; 21: 2294-8.
32. Yuen MF, Yuan HJ, Wong DK et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 1610-14.
33. Fang ZL, Sabin CA, Dong BQ et al. HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol 2008; 103: 2254-62.
34. Yuan JM, Ambinder A, Fan Y, Gao YT, Yu MC, Groopman JD. Prospective evaluation of hepatitis B 1762(T)/1764(A) mutations on hepatocellular carcinoma development in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2009; 18: 590-4.